Clinical trial cost per patient was highest in the blood therapeutic area, ranging between 200 thousand and 422 thousand U.S. dollars with a median of some 311 thousand dollars. This statistic shows the estimated per patient trial costs by therapeutic area, for the period 2015-2017.

This statistic shows the estimated average per-patient biopharmaceutical clinical trial costs in the United States in 2013, by selected condition. In that year the cost per patient for clinical trials for new medicines related to oncology were estimated to be around 59,500 dollars.

This statistic shows the estimated per drug trial costs by therapeutic area, for the period 2015-2017. Clinical trial cost per drug was the highest for cardiovascular drugs, ranging between 74 million and 183 million U.S. dollars with a median of 141 million dollars.

Snapshot img

Clinical Trial Imaging Market Size 2024-2028

The clinical trial imaging market size is forecast to increase by USD 551.3 million at a CAGR of 7.5% between 2023 and 2028.

The market is experiencing significant growth due to the increasing investment in drug development for chronic diseases. Imaging techniques, such as Computed Tomography (CT), play a crucial role in clinical trials by providing valuable data for drug efficacy and safety assessments. Patient comfort is a key trend in this market, as Breast imaging technologies are being developed to minimize patient discomfort and improve the overall trial experience. Data management services are also gaining importance to ensure accurate and efficient handling of imaging data. Strict regulations, however, pose a challenge to market growth, requiring strong data security and compliance measures. Overall, the market is expected to continue its expansion, driven by the need for advanced imaging technologies to support the development of new treatments.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

The integration of medical imaging technologies in clinical trials has revolutionized the biotechnology and pharmaceutical industries. By providing valuable insights into various health conditions, these advanced imaging techniques contribute significantly to the development of new therapeutics and treatments. In the realm of clinical trials, imaging technologies play a pivotal role in assessing the efficacy and safety of new drugs and therapies. Biotechnology and pharmaceutical companies increasingly rely on these technologies to gather data on disease progression, treatment response, and potential side effects. Image analysis software, fueled by artificial intelligence (AI) and machine learning algorithms, is a crucial component of this process. 



These advanced technologies enable the automated detection, measurement, and analysis of various health conditions, including oncology, non-alcoholic steatohepatitis (NASH), neurology, endocrinology, and cardiology. Virtual imaging trials, which utilize AI and machine learning, have gained considerable attention in recent years. These trials allow for remote patient monitoring and data collection, streamlining the clinical trial process and reducing costs. Imaging modalities, such as computed tomography (CT), magnetic resonance imaging (MRI), echocardiography, nuclear medicine (positron emission tomography – PET), x-ray, ultrasound, and optical coherence tomography, are essential tools in the clinical trial landscape.

How is this market segmented and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Modality

  Computed tomography
  Magnetic resonance imaging
  Ultrasound
  Positron emission tomography
  Others


End-user

  Contract research organization
  Pharmaceutical and biotechnology companies
  Research and academic institutes
  Medical device manufacturers


Geography

  North America

    US


  Europe

    Germany
    UK


  Asia

    China
    Japan


  Rest of World (ROW)

By Modality Insights

The computed tomography segment is estimated to witness significant growth during the forecast period.

The market is experiencing notable progressions, with a notable focus on the computed tomography (CT) segment. CT imaging is a vital imaging modality in clinical trials due to its ability to generate detailed cross-sectional images of the body, which are crucial for precise diagnosis and tracking of various medical conditions, including cancer. The rising prevalence of chronic diseases and the demand for early and precise diagnosis have boosted the importance of high-resolution imaging technologies. CT scans are indispensable in evaluating disease progression and treatment effectiveness in clinical trials.

Furthermore, technological innovations in CT imaging, such as photon counting computed tomography (PCCT), are expanding the capabilities of clinical trial imaging. Magnetic Resonance Imaging (MRI), Echocardiography, Nuclear Medicine, Positron Emission Tomography (PET), and X-ray are other significant imaging modalities in clinical trials. MRI offers superior soft tissue contrast and is widely used in neurology, oncology, and cardiology trials. Hence, such factors are fuelling the growth of this segment during the forecast period.

Get a glance at the market report of share of various segments Request Free Sample

The computed tomography segment was valued at USD 317.40 million in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 38% to the growth of the global market during the

Dermatology CRO Market size was valued at USD 4.91 Billion in 2024 and is projected to reach USD 8.32 Billion by 2031, growing at a CAGR of 6.80% during the forecast period 2024-2031.

Global Dermatology CRO Market Drivers

The market drivers for the Dermatology CRO Market can be influenced by various factors. These may include:

Growing Prevalence of Skin Disorders: The need for dermatological services, including clinical trials, is being driven by the increased prevalence of a number of skin conditions, including eczema, psoriasis, acne, and skin cancer.
Growing Need for Cosmetic Procedures: As people attention turns more and more to appearances, there is a greater need for cosmetic dermatological treatments. This, in turn, raises the question of whether clinical research is necessary in this area.
Developments in Dermatological medicines: The demand for clinical trials to evaluate the safety and efficacy of dermatological medicines, such as biologics, targeted therapies, and personalized medicine, is growing.
Growing R&D Investments: More clinical trials and partnerships with CROs are being conducted as a result of pharmaceutical and biotechnology companies’ growing R&D expenditures in dermatology.
Regulatory encourage for Clinical Research: The dermatology CRO industry is expanding as a result of favorable regulatory policies and programs that encourage clinical research. Examples of these include accelerated approval processes and incentives for research on rare diseases.
Technological Advancements in Clinical studies: More sponsors are choosing to undertake dermatology studies as a result of the increased efficiency, lower costs, and increased use of technology like as wearables, telemedicine, and electronic data capture (EDC).
Increasing Trend of R&D Activity Outsourcing: As sponsors may concentrate on their core skills and cut research expenses, there is an increasing trend of outsourcing R&D operations, including clinical trials, to CROs.

Background: Rising expenditure for new cancer medicines is accelerating concerns that their costs will become unsustainable for universal healthcare access. Moreover, early market access of new oncology medicines lacking appropriate clinical evaluation generates uncertainty over their cost-effectiveness and increases expenditure for unknown health gain. Patient-level data can complement clinical trials and generate better evidence on the effectiveness, safety and outcomes of these new medicines in routine care. This can support policy decisions including funding. Consequently, there is a need for improving datasets for establishing real-world outcomes of newly launched oncology medicines.Aim: To outline the types of available datasets for collecting patient-level data for oncology among different European countries. Additionally, to highlight concerns regarding the use and availability of such data from a health authority perspective as well as possibilities for cross-national collaboration to improve data collection and inform decision-making.Methods: A mixed methods approach was undertaken through a cross-sectional questionnaire followed-up by a focus group discussion. Participants were selected by purposive sampling to represent stakeholders across different European countries and healthcare settings. Descriptive statistics were used to analyze quantifiable questions, whilst content analysis was employed for open-ended questions.Results: 25 respondents across 18 European countries provided their insights on the types of datasets collecting oncology data, including hospital records, cancer, prescription and medicine registers. The most available is expenditure data whilst data concerning effectiveness, safety and outcomes is less available, and there are concerns with data validity. A major constraint to data collection is the lack of comprehensive registries and limited data on effectiveness, safety and outcomes of new medicines. Data ownership limits data accessibility as well as possibilities for linkage, and data collection is time-consuming, necessitating dedicated staff and better systems to facilitate the process. Cross-national collaboration is challenging but the engagement of multiple stakeholders is a key step to reach common goals through research.Conclusion: This study acts as a starting point for future research on patient-level databases for oncology across Europe. Future recommendations will require continued engagement in research, building on current initiatives and involving multiple stakeholders to establish guidelines and commitments for transparency and data sharing.

ObjectiveOne key aspect of cancer survivorship is return-to-work. Unfortunately, many cancer survivors face problems upon their return-to-work. For that reason, we developed a hospital-based work support intervention aimed at enhancing return-to-work. We studied effectiveness of the intervention compared to usual care for female cancer patients in a multi-centre randomised controlled trial.MethodsBreast and gynaecological cancer patients who were treated with curative intent and had paid work were randomised to the intervention group (n = 65) or control group (n = 68). The intervention involved patient education and support at the hospital and improvement of communication between treating and occupational physicians. In addition, we asked patient's occupational physician to organise a meeting with the patient and the supervisor to make a concrete gradual return-to-work plan. Outcomes at 12 months of follow-up included rate and time until return-to-work (full or partial), quality of life, work ability, work functioning, and lost productivity costs. Time until return-to-work was analyzed with Kaplan-Meier survival analysis.ResultsReturn-to-work rates were 86% and 83% (p = 0.6) for the intervention group and control group when excluding 8 patients who died or with a life expectancy of months at follow-up. Median time from initial sick leave to partial return-to-work was 194 days (range 14–435) versus 192 days (range 82–465) (p = 0.90) with a hazard ratio of 1.03 (95% CI 0.64–1.6). Quality of life and work ability improved statistically over time but did not differ statistically between groups. Work functioning and costs did not differ statistically between groups.ConclusionThe intervention was easily implemented into usual psycho-oncological care and showed high return-to-work rates. We failed to show any differences between groups on return-to-work outcomes and quality of life scores. Further research is needed to study which aspects of the intervention are useful and which elements need improvement.Trial RegistrationNederlands Trial Register (NTR) 1658

Healthcare Contract Research Outsourcing Market size was valued at USD 43.22 Billion in 2024 and is projected to reach USD 75.66 Billion by 2031, growing at a CAGR of 7.25% during the forecast period 2024-2031.

Global Healthcare Contract Research Outsourcing Market Drivers

The market drivers for the Healthcare Contract Research Outsourcing Market can be influenced by various factors. These may include:

Increasing Research and Clinical Trial Involvement: There has been an increase in research and development activity in the biotechnology and pharmaceutical sectors, which has raised the need for clinical trial outsourcing. Healthcare CROs are essential to the success of these trials and the expansion of the market as a whole.

Time savings and cost effectiveness: Drug development can proceed more quickly and with lower operating expenses for pharmaceutical and biotech businesses that outsource their clinical research operations to CROs. CROs frequently have specialized infrastructure and knowledge, which boosts productivity and shortens turnaround times.

Global Clinical Trials Industry: The increasing number of clinical trials being done in different parts of the world has led to the demand for CROs with local knowledge who can manage a variety of trial populations and negotiate regulatory environments.

The intricacy of the drug development process: With developments in personalized medicine, genetics, and medical research, the process of developing new drugs has grown increasingly intricate. To take use of CROs’ specialized resources and skills, pharmaceutical corporations outsource different parts of clinical trials to them.

Strategic Emphasis on Fundamental Skills: Many biotech and pharmaceutical businesses would rather outsource their clinical research operations to specialized CROs and concentrate on their core skills, such marketing and drug discovery. They are able to distribute resources more skillfully as a result.

Snapshot img

Eclinical Solutions Market Size 2024-2028

The eclinical solutions market size is forecast to increase by USD 12.77 billion at a CAGR of 15.26% between 2023 and 2028.

The eClinical solutions market is experiencing significant growth, driven by the increasing number of clinical trials and the rising need for helathcare automation and process optimization. As trials become more complex, organizations are adopting eClinical technologies to enhance efficiency, data accuracy, and patient safety. Additionally, the outsourcing of clinical trial processes is gaining traction as companies seek to reduce costs and improve operational effectiveness.
However, high clinical trial costs remain a challenge, requiring innovative strategies to balance cost-effectiveness with regulatory compliance. Despite this, the market continues to expand due to the advantages of faster trial completion times and streamlined data management.
Castor EDC is a key player in this space, offering eClinical solutions for contract research organizations (CROs). Their platform supports the successful management of hybrid and decentralized trials, enabling more flexible, scalable, and patient-centric clinical research in the future.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

The market encompasses software designed to streamline and enhance clinical trials In the healthcare industry. With the enormous amount of data generated during clinical trials, there is a rising number of institutions, including cancer centers, placing an emphasis on clinical trials and observational studies to drive research funding and innovation. Solutions enable technology adoption for improved patient engagement, data management, and site management. 
Internet of Things plays a significant role in this market, allowing for real-time data collection and analysis. The trio of patients, technology, and healthcare professionals collaborate to leverage these solutions, leading to increased efficiency and accuracy in clinical research. Despite the minor challenges in implementation and integration, the market continues to grow, driven by the need for more effective and efficient clinical trials.

How is this Industry segmented and which is the largest segment?

The report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

End-user

  Pharmaceutical and biotechnology companies
  Contract research organizations
  Consulting service companies
  Medical device manufacturers
  Others


Deployment

  Cloud-based
  On-premises


Product

  Electronic Data Capture (EDC) and Clinical Data Management Systems (CDMS)
  Clinical Trial Management Systems (CTMS)
  Clinical Analytics Platforms
  Randomization and Trial Supply Management (RTSM)
  Clinical Data Integration Platforms
  Electronic Clinical Outcome Assessment (eCOA)
  Safety Solutions
  Electronic Trial Master File (eTMF)
  Electronic Consent (eConsent)


Geography

  North America

    US


  Europe

    Germany
    UK


  Asia

    China
    Japan


  Rest of World (ROW)

By End-user Insights

The pharmaceutical and biotechnology companies segment is estimated to witness significant growth during the forecast period.

Clinical trials are a crucial aspect of bringing new drugs and biologics to market In the healthcare industry. Pharmaceutical and biotechnology companies invest substantial resources into clinical research, which involves testing drugs on animals and humans. However, clinical trials can be complex and costly, with the potential for significant financial and time losses if trials fail to meet endpoints or if clinical trial sites do not meet regulatory standards. Ensuring the integrity and efficiency of clinical trials is essential for these companies, as well as for healthcare providers, academic universities, research centers, and contract research organizations (CROs). The use such as Clinical Trial Management Systems (CTMS), Clinical Data Management Systems (CDMS), and Electronic Data Capture (EDC) systems, has become increasingly important in addressing the challenges of clinical trials. These technologies enable real-time access to clinical data, improve clinical trial processes, enhance data standardization, and increase cost efficiency. Furthermore, the integration of the Internet of Things (IoT) and digitization of healthcare has led to the adoption of these solutions by smaller enterprises and developing markets. Clinical trials involve various phases, including vaccine development, clinical trials, observational studies, and drug development. The benefits of solutions extend to all these phases, improving site performance, retention, and clinical researchers' ability to manage drug candidates and cli

Clinical Trial Platform Market Outlook

The global clinical trial platform market size was estimated at USD 3.5 billion in 2023 and is projected to reach USD 9.7 billion by 2032, growing at a CAGR of 12.1% during the forecast period. This robust growth is driven by the increasing complexity of clinical trials, the need for faster and more efficient drug development processes, and the growing adoption of advanced technologies in clinical research.

A significant growth factor in the clinical trial platform market is the increasing incidence of chronic diseases worldwide, necessitating the development of new and effective treatments. Chronic conditions such as cancer, diabetes, and cardiovascular diseases require extensive research and clinical trials to develop new therapeutics. This demand drives the need for more sophisticated and efficient clinical trial platforms that can handle complex data and streamline the trial process. Additionally, advancements in biotechnology and personalized medicine are contributing to the market's growth by requiring more specialized and adaptive clinical trial platforms.

Another key driver is the regulatory landscape that governs clinical trials. Regulatory bodies such as the FDA in the United States and the EMA in Europe have stringent requirements for the approval of new drugs and treatments. These regulations necessitate the use of comprehensive and compliant clinical trial platforms that can ensure data integrity, patient safety, and adherence to protocols. The need to meet regulatory standards drives pharmaceutical and biotechnology companies to invest in advanced clinical trial platforms that can facilitate easier compliance and reduce the time to market.

The digital transformation in the healthcare and pharmaceutical sectors also plays a crucial role in the growth of the clinical trial platform market. The adoption of artificial intelligence (AI), machine learning, and big data analytics in clinical trials accelerates the data collection and analysis processes, leading to more efficient and cost-effective trials. These technologies enable real-time monitoring, predictive analytics, and improved patient recruitment and retention, thereby enhancing the overall efficiency and success rates of clinical trials.

Clinical Trial Data Analytics plays a pivotal role in transforming the way clinical trials are conducted. By leveraging advanced data analytics, researchers can gain deeper insights into trial data, enabling more informed decision-making and enhancing the accuracy of trial outcomes. This approach not only improves the efficiency of clinical trials but also helps in identifying potential issues early in the trial process, thereby reducing risks and costs. The integration of data analytics into clinical trial platforms allows for real-time monitoring and analysis, facilitating faster and more reliable results. As the demand for precision medicine grows, the importance of data analytics in clinical trials continues to rise, driving innovation and improving patient outcomes.

Regionally, North America dominates the clinical trial platform market due to high R&D investments, a strong pharmaceutical industry presence, and favorable regulatory frameworks. The region's advanced healthcare infrastructure and emphasis on innovation further propel market growth. Europe follows, driven by similar factors and a growing focus on clinical research. The Asia Pacific region is expected to witness the highest growth rate, attributed to increasing clinical trial activities, rising healthcare expenditures, and improving healthcare infrastructure.

Component Analysis

The clinical trial platform market is segmented by component into software and services. The software segment encompasses various applications such as Electronic Data Capture (EDC), Clinical Trial Management Systems (CTMS), and eCOA (electronic Clinical Outcome Assessment). The increasing adoption of these software solutions is driven by their ability to streamline clinical trial processes, enhance data accuracy, and improve regulatory compliance. EDC systems, for instance, enable real-time data entry and monitoring, reducing the risk of errors and facilitating efficient data management.

CTMS solutions are pivotal in managing the operational aspects of clinical trials, including planning, tracking, and reporting. They improve trial efficiency by providing a centralized platform for managing trial

The global adrenocortical carcinoma (ACC) drugs market is a niche but rapidly evolving therapeutic area characterized by a relatively small patient population but significant unmet medical needs. While precise market size figures for 2025 are unavailable in the provided data, considering a typical CAGR (Compound Annual Growth Rate) for specialized oncology drugs of 8-12% between 2019-2024 and extrapolating this for the future, the market value in 2025 could be estimated to be between $300 million and $500 million (assuming a base year value near the lower end of this range, factoring in market entry of newer drugs and their impact on growth). Key drivers include increasing ACC incidence rates, growing awareness among healthcare professionals and patients, and ongoing research and development efforts focused on novel therapeutic approaches. Current treatment options are limited and often associated with significant side effects, creating a strong impetus for innovative therapies. The market is segmented by drug type (e.g., targeted therapies, chemotherapies, immunotherapies) and application (e.g., first-line treatment, second-line treatment). Companies such as Bristol-Myers Squibb, Eli Lilly, and others are actively involved in research and development or commercialization within this field. Market restraints include the relatively low prevalence of ACC, the complexity of clinical trials in this rare cancer, and associated high development costs. The forecast period (2025-2033) suggests continued market expansion, fueled by the introduction of new and more effective therapies. Regional variations in healthcare infrastructure, access to advanced treatments, and regulatory frameworks will influence market performance. North America and Europe are expected to dominate the market initially due to better access to advanced medical treatments and higher healthcare spending. However, growth in emerging markets like Asia-Pacific is anticipated due to rising healthcare expenditure, increasing awareness, and an expanding patient population. The continued focus on personalized medicine and the development of targeted therapies tailored to specific ACC subtypes are critical aspects shaping future market dynamics. This growth will necessitate a concerted effort among pharmaceutical companies, researchers, and regulatory bodies to ensure equitable access to life-saving therapies for ACC patients globally.

BackgroundThe ALTA-1 L trial and EXP-3B arm of NCT01970865 trial found that both brigatinib and lorlatinib showed durable and robust responses in treating ALK-positive non-small cell lung cancer (NSCLC) patients. However, brigatinib and lorlatinib treatments are costly and need indefinite administration until the disease progression. Thus, it remains uncertain whether using brigatinib followed by lorlatinib before chemotherapy is cost-effective compared to reserving these two drugs until progression after chemotherapy.MethodsWe used a Markov model to assess clinical outcomes and healthcare costs of treating ALK-positive NSCLC individuals with brigatinib followed by lorlatinib before chemotherapy versus a strategy of reserving these drugs until progression after chemotherapy. Transition probabilities were estimated using parametric survival modeling based on multiple clinical trials. The drug acquisition costs, adverse events costs, administration costs were extracted from published studies before and publicly available data. We calculated lifetime direct healthcare costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios from the perspective of a United States payer.ResultsOur base-case analysis indicated that the incremental cost-effectiveness ratios of using first-line brigatinib followed by lorlatinib compared with second-line brigatinib followed by lorlatinib is $-400,722.09/QALY which meant that second-line brigatinib followed by lorlatinib had less costs and better outcomes. Univariate sensitivity analysis indicated the results were most sensitive to the cost of brigatinib. Probability sensitivity analysis revealed that using brigatinib followed by lorlatinib before chemotherapy had a 0% probability of cost-effectiveness versus delaying these two drugs until progression after chemotherapy at a willingness-to-pay threshold of $150,000 per QALY. Sensitivity analyses conducted revealed the robustness of this result, as incremental cost-effectiveness ratios never exceeded the willingness-to-pay threshold.ConclusionUsing brigatinib as first-line treatment followed by lorlatinib for ALK-positive NSCLC may not be cost-effective given current pricing from the perspective of a United States payer. Delaying brigatinib followed by lorlatinib until subsequent lines of treatment may be a reasonable strategy that could limit healthcare costs without affecting clinical outcomes. More mature data are needed to better estimate cost-effectiveness in this setting.

The size of the Virtual Clinical Trials Industry market was valued at USD 9.52 Million in 2023 and is projected to reach USD 17.79 Million by 2032, with an expected CAGR of 9.34% during the forecast period. The virtual clinical trials sector is moving very fast because of the recognition of a more efficient and adaptable way of conducting clinical research in recent times. Virtual clinical trials use digital technologies to conduct studies from remote settings; participants can thus participate from their homes using telemedicine, mobile health apps, and wearable devices to collect data. The method has improved on patient recruitment, retention, and compliance, especially among patients who would otherwise be discouraged from participating in traditional trials. The main drivers of growth in this sector are a continued focus on patient-centric trial designs, technology advancements, as well as the COVID-19 pandemic, which previously accelerated the spread of remote trial design. Regulatory bodies have also started to embrace virtual approaches that can offer the potential for more cost-effective and efficient trials for some time now. The market includes various stakeholders, like pharma companies, CROs, and technology providers. Those players are investing in innovative solutions to streamline the processes under a trial, data management, and regulatory compliance. Geographical Areas: North America is leading in the market based on the present healthcare infrastructure and technological advancement. However, the Asian Pacific is accelerating rapidly, which gets driven by increasing investments in the clinical research area along with a rise in focus on digital health solutions. Overall, virtual clinical trials is going to continue seeing growth because that is an element of this systemic shift toward more accessible, efficient, and patient-centered approaches in clinical research. Key drivers for this market are: Growing Digitization in Healthcare Sector, Technological Advancements in Virtual Clinical Trials; Prevalence of Chronic Disease. Potential restraints include: Challenges Associated with the Virtual Clinical Trials. Notable trends are: The Oncology Segment is Expected to Occupy a Significant Share of the Market Over the Forecast Period.

According to the Cognitive Market Research Report, the Clinical Trials Imaging Market size in 2023 was XX Million and is projected to have a compounded annual growth rate of XX% from 2024 to 2031. The drivers of this industry are Advancements in imaging technology is accelerating the growth of the marke and An increasing number of organizations which are engaged in contract research, is accelerating the growth of the market With XX million of the market revenue in 2023 and a market share of almost XX%, North America emerged as the largest market for clinical trials imaging market globally. There are a variety of participants in the clinical trial imaging market, and competition is expected to intensify with the upcoming arrival of new firms. To maintain a competitive advantage, well-established leaders in the field constantly reinvent their technologies with an emphasis on reliability, safety, and efficiency.

Market Dynamics of Clinical Trial Imaging

Key Drivers

Advancements in imaging technology are accelerating the growth of the market.

The need for imaging services has grown at an extraordinary rate over the past two to three decades. When it comes to computed tomography (CT) and ultrasound (US), new modalities have either been created (such as positron emission tomography, or PET) or have seen substantial improvement. Patient care has been significantly impacted by the tremendous advancement in cross-sectional imaging technology as well as the quick development and clinical integration of interventional radiology. A significant change is currently taking place in the imaging specialist's workplace. The image industry has seen a change because of digital data and technology. Patients now have more access to imaging data thanks to its electronic capture, interpretation, transmission, and storage, which also helps the doctors who refer them. Access to imaging interpretations is nearly instantaneous on their workplace PCs, and it is available earlier and more easily. They may virtually instantly access these tests on their workplace computers, and imaging interpretations are now more easily and sooner available. Improved image analysis with AI and machine learning algorithms speeds up medication development and lowers trial expenses. Efficient data exchange and cooperation are further enabled by the increasing popularity of decentralized trials and remote imaging technology. Enhancing drug development tactics in the pharmaceutical and biotechnology sectors, these developments increase efficiency and precision in clinical trial design and execution. For instance, Innovation and Research are Supported by Median's Clinical Trial Imaging Solutions which has led growth of market for imaging from cancer clinical trials, Median iCRO assists life science firms in turning imaging data into insights that may change people's lives. Through the extraction of the best imaging biomarkers, their cutting-edge technologies and methods, such as AI and machine learning, transformed the use of medical pictures in clinical trials and established new benchmarks for the creation of novel treatments.(Source:https://mediantechnologies.com/clinical-trials/) Therefore, remarkable progress in cross-sectional imaging technology and the rapid growth and practical application of interventional radiology are regarded as the technological advancements to drive the clinical trial imaging market.

An increasing number of organizations which are engaged in contract research, is accelerating the growth of the market

Clinical trial management services are offered by Contact Research Organizations, whereas drug research, manufacturing, laboratory, and bioanalytical services are provided by laboratory CROs. Sponsors usually contract out these services to save money on developing new medications. Although scale and dependability have long been associated with CROs, this is starting to change as more businesses realize their distinct benefits. These CROs are setting new benchmarks for excellence in drug development collaborations with their flexibility, individualized service, and access to senior-level knowledge. While pharmaceutical corporations strive to reduce expenses, CROs appear to be accepting greater risks and duties in return for greater returns. The pharmaceutical industry finds this strategy attractive since it lets them focus on early-stage development and drug discove...

The Patient-Derived Xenograft (PDX) market is experiencing robust growth, driven by the increasing demand for personalized medicine and the rising prevalence of cancer globally. A 16.66% CAGR from 2019-2033 indicates a significant expansion, fueled by the PDX models' ability to accurately mimic human tumor behavior, enabling more effective drug development and personalized treatment strategies. Key market drivers include the growing adoption of precision oncology, increasing investments in research and development, and the limitations of traditional preclinical models in predicting clinical outcomes. The market is segmented by type (e.g., tumor type-specific PDXs, organ-specific PDXs) and application (drug discovery and development, personalized medicine, translational research). Leading companies are strategically investing in advanced technologies and expanding their service portfolios to cater to the growing demand. Competitive strategies focus on collaborations, acquisitions, and the development of innovative PDX models. The North American market currently holds a significant share, driven by strong regulatory frameworks and substantial research funding. However, the Asia-Pacific region is projected to witness rapid growth due to increasing healthcare expenditure and rising cancer incidence. The market faces restraints such as high costs associated with PDX model development and maintenance, as well as ethical considerations related to animal use. Nevertheless, the overall market outlook remains positive, with substantial growth anticipated over the forecast period. Further analysis reveals a strong correlation between the increasing adoption of precision oncology and the market expansion of PDXs. This is further substantiated by the ongoing investments in research and development by pharmaceutical and biotechnology companies, seeking to improve cancer treatment efficacy through personalized approaches. The market segmentation indicates a diversity of applications and types, highlighting the versatility of PDX models and contributing to the sustained market growth. The geographical segmentation highlights the regional differences in market penetration, with North America as the current leader but Asia-Pacific poised for significant expansion in the coming years. The projected growth rate suggests a continued high demand for PDX models, driven by the limitations of traditional methods and the increasing need for effective, personalized cancer therapies. This emphasizes the importance of addressing the restraints through technological advancements and cost-effective solutions to fully unlock the market's potential.

Snapshot img

Cancer Registry Software Market Size 2024-2028

The cancer registry software market size is forecast to increase by USD 97.1 million at a CAGR of 12.75% between 2023 and 2028.

The growing prevalence of cancer cases is the key driver of the cancer registry software market. CDC is a key player, specializing in providing advanced cancer registry software solutions, including Registry Plus. These systems facilitate accurate and efficient data management for healthcare organizations, enabling effective tracking, analysis, and reporting of cancer patient information as well as supporting cancer immunotherapy and cancer diagnostics. By supporting improved patient care and research outcomes, CDC's solutions are essential in addressing the increasing demand for comprehensive cancer data management. 
Additionally, data privacy and security concerns are driving the market, as healthcare organizations prioritize protecting sensitive patient information. These trends are shaping the market, which is expected to continue its growth trajectory In the coming years.

What will be the Size of the Cancer Registry Software Market During the Forecast Period?

Request Free Sample

The market is experiencing significant growth due to the increasing incidence of cancer and the need for efficient and accurate data management In the healthcare industry. With the adoption of Electronic Health Records (EHRs) and the shift towards evidence-based medicine, cancer registry software solutions have become essential tools for medical professionals to track cancer treatment, therapeutics, and patient outcomes. 
These solutions enable the collection and analysis of data on cancer prevalence, diagnostics, and specific area-focused cancer incidence. They provide valuable insights into cancer-specific outcomes, including chemotherapy, surgery, supportive treatments, and post-endoscopic resection. Furthermore, regulatory guidance documents mandate the use of cancer registry software to ensure compliance with healthcare standards and reduce healthcare costs.
Medical professionals rely on these software solutions to improve patient care and support the ongoing research and development of new cancer treatments.

How is this Cancer Registry Software Industry segmented and which is the largest segment?

The cancer registry software industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

End-user

  Government and third party
  Pharma biotech and medical device companies
  Hospitals and medical practice
  Private payers
  Research institutes


Type

  Stand-alone software
  Integrated software


Deployment

  On-premise
  Cloud


Component

  Commercial
  Public


Geography

  North America

    Canada
    US


  Europe

    Germany
    Italy


  Asia

    China


  Rest of World (ROW)

By End-user Insights

The government and third party segment is estimated to witness significant growth during the forecast period. Cancer registry software plays a pivotal role in managing data related to cancer cases for government hospitals and third-party agencies. This software facilitates the collection, management, and analysis of data on cancer incidence, prevalence, and mortality rates. This information is essential for public health planning, resource allocation, and policy development. By identifying trends and patterns, governments and agencies can target high-risk populations, address geographic disparities, and recognize emerging cancer types. Cancer registry software enhances the quality of cancer care by enabling the evaluation of treatment practices against clinical guidelines and benchmarking outcomes against standards. The software supports seamless data integration and interoperability with healthcare systems, ensuring coordinated care for cancer patients.

Medical professionals and patients alike benefit from improved cancer care through evidence-based medicine, cancer-specific outcomes, and research institutes. Software solutions cater to various cancer types, including lung cancer, and support cancer staging, treatment, disease management, diagnostics, chemo, surgery, and supportive therapies. These solutions integrate with electronic health records (EHR), enabling secure data storage and access to essential health information. Data security and security protocols are prioritized to protect patient privacy and prevent medical identity theft. Cancer registry software supports population health management, healthcare cost containment, and chronic disease management. It aligns with healthcare quality goals and streamlines hospital workflows, making it an essential tool for oncology departments, clinics, hospitals, medical practices, pharmaceutical, biotech, and medical de

All individuals diagnosed with cancer from 2000 to 2007 were identified in the Cancer Register of Southern Sweden, but only individuals who were also identified in the Population Register of Scania were included in this cohort. Age- and gender-matched controls were identified in the Population Register of Scania. The controls were reconciled with the cancer registry in southern Sweden so that they had no prior diagnosis of cancer and with the Population Register of Scania that they were alive at time of diagnosis to the matched case. Also spouses to cancer patients were used as controls.

For each individual, healthcare costs were monitored related to the date of diagnosis. Costs for outpatient care, inpatient care, number of days in hospital and medications were included. Costs were also calculated for the controls.

Other information available about the individuals in the cohort are age, sex, domicile, type of tumor and medication.

Purpose:

To study the health cost per individual in relation to mortality and comorbidity.

Dataset includes the study controls (individuals matched by age and sex ) Also spouses to cancer patients were included in the control group.

The global pancreatic cancer therapeutics market is a rapidly evolving landscape characterized by significant unmet needs and ongoing innovation. While pancreatic cancer remains a challenging disease with a notoriously poor prognosis, advancements in targeted therapies, immunotherapies, and supportive care are driving market growth. The market is segmented by drug type (e.g., chemotherapy, targeted therapy, immunotherapy) and application (e.g., first-line, second-line treatment). Key players like Eli Lilly, Roche, Novartis, Pfizer, and Shire are heavily invested in R&D, fueling the development of novel treatment strategies. The market's substantial size, estimated at $X billion in 2025 (assuming a logical estimation based on similar oncology markets and reported CAGRs), reflects the high prevalence of pancreatic cancer and the substantial cost associated with its treatment. A compound annual growth rate (CAGR) of Y% (estimated based on industry benchmarks) projected between 2025 and 2033 indicates considerable future market expansion. Growth is fueled by increased cancer incidence, improved diagnostic techniques leading to earlier detection, and the ongoing development and approval of more effective therapies. Despite the significant growth potential, the market faces challenges. High treatment costs, limited treatment options with durable responses, and the aggressive nature of pancreatic cancer limit market penetration. Regional variations in healthcare infrastructure and access to advanced therapies also contribute to market segmentation. North America, with its advanced healthcare systems and high per-capita healthcare expenditure, holds a substantial market share. However, emerging economies in Asia Pacific and other regions are projected to demonstrate faster growth due to rising cancer rates and increasing healthcare investments. The focus is shifting towards personalized medicine and combination therapies that target specific genetic mutations and improve patient outcomes, thereby offering new avenues for growth in the coming decade. Regulatory approvals, pricing strategies, and reimbursement policies play crucial roles in shaping market dynamics.

The global clinical trials outsourcing market size was valued at USD 43.1 billion in 2022 and is projected to reach USD 84.3 billion by 2033, growing at a CAGR of 7.2% from 2025 to 2033. The growth of the market is attributed to the increasing prevalence of chronic diseases, rising healthcare costs, and the growing need for efficient and cost-effective clinical trials. The clinical trials outsourcing market is segmented by type into phase I, phase II, phase III, and phase IV. The phase III segment accounted for the largest share of the market in 2022 and is expected to maintain its dominance during the forecast period. The growth of this segment can be attributed to the increasing number of clinical trials being conducted in the later stages of drug development. By application, the cancer segment accounted for the largest share of the market in 2022 and is expected to continue to hold a significant share during the forecast period. The growing prevalence of cancer and the increasing investment in cancer research are contributing to the growth of this segment. North America accounted for the largest share of the clinical trials outsourcing market in 2022 and is expected to remain the dominant region during the forecast period. The presence of well-established and experienced clinical research organizations (CROs), favorable government policies, and a large number of pharmaceutical and biotechnology companies are factors contributing to the growth of the market in this region.

The Contract Research Organization (CRO) Solutions market is experiencing robust growth, driven by the increasing demand for outsourced clinical research services by pharmaceutical and biotechnology companies. This surge is fueled by several factors, including the rising complexity of drug development, the need for accelerated timelines, and the cost-effectiveness of outsourcing non-core functions. The market size in 2025 is estimated at $50 billion, exhibiting a Compound Annual Growth Rate (CAGR) of 7% from 2025 to 2033. This projection reflects the continued expansion of clinical trials, particularly in emerging therapeutic areas like oncology, immunology, and cell therapy, which necessitate specialized CRO services. Key segments like early-phase development and laboratory services are expected to witness above-average growth, driven by the increasing adoption of innovative technologies and advanced analytics in drug discovery and development. Geographical expansion, particularly in developing regions like Asia-Pacific, further contributes to market expansion. Leading CROs are strategically investing in expanding their service portfolios, enhancing technological capabilities, and forging strategic partnerships to capitalize on the growing market opportunities. The competitive landscape is marked by the presence of both large multinational corporations and specialized niche players. Consolidation and acquisitions are expected to remain significant trends, as larger players seek to broaden their service offerings and geographic reach. Regulatory changes and evolving ethical considerations within the clinical research landscape present both challenges and opportunities for CROs, requiring adaptation and strategic planning to ensure sustained growth. Despite potential restraints such as pricing pressures and increasing competition, the overall outlook for the CRO market remains positive, driven by the persistent demand for efficient and cost-effective drug development solutions.